Latest Insider Transactions at Neogenomics Inc (NEO)
This section provides a real-time view of insider transactions for Neogenomics Inc (NEO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of NEOGENOMICS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of NEOGENOMICS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 10
2022
|
Lynn A. Tetrault Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,556
+22.15%
|
-
|
|
Jun 10
2022
|
David Daly Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,556
+47.52%
|
-
|
|
Jun 10
2022
|
Rachel A Stahler Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,556
+42.17%
|
-
|
|
Jun 10
2022
|
Alison L. Hannah Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,556
+12.65%
|
-
|
|
Jun 10
2022
|
Bruce K Crowther Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,556
+19.28%
|
-
|
|
Jun 10
2022
|
Stephen M Kanovsky Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,556
+38.59%
|
-
|
|
Jun 10
2022
|
Michael Aaron Kelly Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,556
+43.24%
|
-
|
|
Jun 01
2022
|
Vishal Sikri President Advanced Diagnostics |
BUY
Grant, award, or other acquisition
|
Direct |
148,455
+50.0%
|
-
|
|
May 18
2022
|
Lynn A. Tetrault Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,334
+7.85%
|
$23,338
$7.27 P/Share
|
|
Apr 28
2022
|
William Bonello Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,727
+2.9%
|
$40,089
$7.52 P/Share
|
|
Apr 01
2022
|
Douglas Matthew Brown Chief Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
82,305
+34.15%
|
-
|
|
Apr 01
2022
|
David Sholehvar President, Clinical Services |
BUY
Grant, award, or other acquisition
|
Direct |
30,864
+50.0%
|
-
|
|
Apr 01
2022
|
William Bonello Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
82,305
+30.7%
|
-
|
|
Mar 08
2022
|
William Bonello Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.61%
|
$35,000
$7.52 P/Share
|
|
Mar 07
2022
|
William Bonello Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,209
-3.15%
|
$57,762
$18.29 P/Share
|
|
Mar 02
2022
|
Douglas Matthew Brown Chief Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
867
-1.12%
|
-
|
|
Mar 02
2022
|
William Bonello Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
620
-0.61%
|
-
|
|
Mar 02
2022
|
George Cardoza President & COO, Lab Ops |
SELL
Payment of exercise price or tax liability
|
Direct |
839
-0.34%
|
-
|
|
Mar 02
2022
|
Cynthia J Dieter Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
137
-0.73%
|
-
|
|
Mar 01
2022
|
Gina M Wallar President, Pharma Services |
BUY
Grant, award, or other acquisition
|
Direct |
11,677
+25.88%
|
-
|
|
Mar 01
2022
|
Douglas Matthew Brown Chief Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,030
+31.2%
|
-
|
|
Mar 01
2022
|
William Bonello Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
397
-0.39%
|
-
|
|
Mar 01
2022
|
William Bonello Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,869
+28.46%
|
-
|
|
Mar 01
2022
|
George Cardoza President & COO, Lab Ops |
SELL
Payment of exercise price or tax liability
|
Direct |
503
-0.2%
|
-
|
|
Mar 01
2022
|
Cynthia J Dieter Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,341
+33.22%
|
-
|
|
Mar 01
2022
|
Mark Mallon Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
142,457
+27.9%
|
-
|
|
Mar 01
2022
|
Halley E Gilbert Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
42,036
+22.19%
|
-
|
|
Jan 11
2022
|
Kathryn B Mc Kenzie Chief Sustainability/Risk Ofcr |
BUY
Exercise of conversion of derivative security
|
Direct |
2,100
+4.08%
|
$18,900
$9.07 P/Share
|
|
Dec 30
2021
|
Douglas Matthew Brown Chief Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,572
+42.0%
|
-
|
|
Dec 30
2021
|
Halley E Gilbert Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,858
+30.38%
|
-
|
|
Dec 30
2021
|
Cynthia J Dieter Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,643
+44.76%
|
-
|
|
Dec 30
2021
|
Jennifer Balliet VP and Chief Culture Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,400
+30.56%
|
-
|
|
Dec 30
2021
|
William Bonello Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,400
+25.7%
|
-
|
|
Dec 30
2021
|
Kathryn B Mc Kenzie Chief Sustainability/Risk Ofcr |
BUY
Grant, award, or other acquisition
|
Direct |
30,572
+39.28%
|
-
|
|
Dec 30
2021
|
George Cardoza President & COO, Lab Ops |
BUY
Grant, award, or other acquisition
|
Direct |
61,143
+19.94%
|
-
|
|
Dec 30
2021
|
Mark Mallon Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
152,858
+40.39%
|
-
|
|
Dec 30
2021
|
Clive Morris President of Inivata |
BUY
Grant, award, or other acquisition
|
Direct |
30,572
+42.55%
|
-
|
|
Dec 30
2021
|
Gina M Wallar President, Pharma Services |
BUY
Grant, award, or other acquisition
|
Direct |
15,286
+41.78%
|
-
|
|
Dec 22
2021
|
Kevin C Johnson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,334
+8.19%
|
$23,338
$7.27 P/Share
|
|
Dec 22
2021
|
Kathryn B Mc Kenzie Chief Sustainability/Risk Ofcr |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+23.05%
|
$45,000
$9.07 P/Share
|
|
Dec 21
2021
|
Kathryn B Mc Kenzie Chief Sustainability/Risk Ofcr |
SELL
Open market or private sale
|
Direct |
1,846
-13.64%
|
$64,610
$35.0 P/Share
|
|
Dec 06
2021
|
Mark Mallon Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
17,000
+18.94%
|
$510,000
$30.63 P/Share
|
|
Nov 30
2021
|
William Bonello Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+38.18%
|
$175,000
$7.52 P/Share
|
|
Nov 26
2021
|
Douglas Matthew Brown Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
33,334
-74.11%
|
$1,200,024
$36.85 P/Share
|
|
Nov 24
2021
|
William Bonello Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
25,000
-61.77%
|
$925,000
$37.13 P/Share
|
|
Nov 24
2021
|
William Bonello Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+38.18%
|
$200,000
$8.03 P/Share
|
|
Nov 24
2021
|
Douglas Matthew Brown Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
33,333
-42.56%
|
$1,199,988
$36.84 P/Share
|
|
Nov 23
2021
|
Douglas Matthew Brown Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
33,333
-29.86%
|
$1,233,321
$37.19 P/Share
|
|
Nov 10
2021
|
David Daly Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,623
+50.0%
|
-
|
|
Oct 11
2021
|
Lynn A. Tetrault Director |
BUY
Grant, award, or other acquisition
|
Direct |
838
+2.29%
|
-
|